179636-96-5

Upstream product

• 100-46-9 benzylamine 
• 177947-76-1 (3R)-1-(tert-butoxycarbonyl)-3-[(methane-sulfonyloxy)methyl]pyrrolidine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 132945-76-7 tert-butyl (3R)-3-cyano-1-pyrrolidinecarboxylate 
• 132945-75-6 (S)-tert-butyl 3-(methylsulfonyloxy)pyrrolidine-1-carboxylate 
• 101469-92-5 (S)-3-hydroxy-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 99735-47-4 (3R)-1-[(R)-1-phenylethyl]-3-(hydroxymethyl)pyrrolidine 

Downstream Products

• 1426096-01-6 1,1-dimethylethyl (3S)-3-{[[(4-bromophenyl)carbonyl](phenylmethyl)amino]methyl}-1-pyrrolidinecarboxylate 
• 1426095-40-0 4-(1-benzofuran-5-yl)-N-{[(3R)-1-cyclopropylcarbonyl-3-pyrrolidinyl]methyl}-N-(phenylmethyl)benzamide 
• 1426095-41-1 4-(1H-benzimidazol-5-yl)-N-{[(3R)-1-cyclopropylcarbonyl-3-pyrrolidinyl]methyl}-N-(phenylmethyl)benzamide 
• 1426095-42-2 N-{[(3R)-1-cyclopropylcarbonyl-3-pyrrolidinyl]methyl}-4'-(methyloxy)-N-(phenylmethyl)-4-biphenylcarboxamide 
• 1426095-43-3 N-{[(3R)-1-cyclopropylcarbonyl-3-pyrrolidinyl]methyl}-4-(1H-indol-6-yl)-N-(phenylmethyl)benzamide 
• 1426095-44-4 N-{[(3R)-1-cyclopropylcarbonyl-3-pyrrolidinyl]methyl}-4-(1H-indol-4-yl)-N-(phenylmethyl)benzamide 
• 1426095-45-5 N-{[(3R)-1-cyclopropylcarbonyl-3-pyrrolidinyl]methyl}-4-(1H-indol-7-yl)-N-(phenylmethyl)benzamide 
• 1426095-46-6 3'-chloro-N-{[(3R)-1-cyclopropylcarbonyl-3-pyrrolidinyl]methyl}-4'-fluoro-N-(phenylmethyl)-4-biphenylcarboxamide 
• 1426096-03-8 4-bromo-N-(phenylmethyl)-N-[(3R)-3-pyrrolidinylmethyl]benzamide hydrochloride 
• 1426096-05-0 4-bromo-N-{[(3R)-1-cyclopropylcarbonyl-3-pyrrolidinyl]methyl}-N-(phenylmethyl)benzamide 
• 1426095-37-5 N-{[(3R)-1-cyclopropylcarbonyl-3-pyrrolidinyl]methyl}-4-(1H-indazol-5-yl)-N-(phenylmethyl)benzamide 
• 1426095-38-6 N-{[(3R)-1-cyclopropylcarbonyl-3-pyrrolidinyl]methyl}-4-(1H-indazol-6-yl)-N-(phenylmethyl)benzamide 
• 1426095-39-7 N-{[(3R)-1-cyclopropylcarbonyl-3-pyrrolidinyl]methyl}-4-(1H-indol-5-yl)-N-(phenylmethyl)benzamide 
• 177945-75-4 (3S)-3-(N-benzyl)aminomethyl-1-[2-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)ethyl]pyrrolidine 

Relevant academic research and scientific papers

FATTY ACID SYNTHASE INHIBITORS

This invention relates to carboxamides and reverse carboxamides according to Formula (I) and the use of carboxamides and reverse carboxamides for the modulation, notably the inhibition of the activity or function of fatty acid synthase (FAS). Suitably, the present invention relates to the use of carboxamides and reverse carboxamides in the treatment of cancer.

Synthesis and serotonergic activity of 3-[2-(pyrrolidin-1- yl)ethyl]indoles: Potent agonists for the h5-HT(1D) receptor with high selectivity over the h5-HT(1B) receptor

The design, synthesis, and biological evaluation of a novel series of 3- [2-(pyrrolidin-1-yl)ethyl]-indoles with excellent selectivity for h5-HT(1D) (formerly 5-HT(1Dα)) receptors over h5-HT(1B) (formerly 5-HT(1Dβ)) receptors are described. Clinically effective antimigraine drugs such as Sumatriptan show little selectivity between h5-HT(1D) and h5-HT(1B) receptors. The differential expression of h5-HT(1D) and h5-HT(1B) receptors in neural and vascular tissue prompted an investigation of whether a compound selective for the h5-HT(1D) subtype would have the same clinical efficacy but with reduced side effects. The pyrrolidine 3b was initially identified as having 9-fold selectivity for h5-HT(1D) over h5-HT(1B) receptors. Substitution of the pyrrolidine ring of 3b with methylbenzylamine groups gave compounds with nanomolar affinity for the h5-HT(1D) receptor and 100-fold selectivity with respect to h5-HT(1B) receptors. Modification of the indole 5-substituent led to the oxazolidinones 24a,b with up to 163-fold selectivity for the h5-HT(1D) subtype and improved selectivity over other serotonin receptors. The compounds were shown to be full agonists by measurement of agonist-induced [35S]GTPγS binding in CHO cells expressed with h5-HT receptors. This study suggests that the h5-HT(1D) and h5-HT(1B) receptors can be differentiated by appropriate substitution of the ligand in the region which binds to the aspartate residue and reveals a large binding pocket in the h5-HT(1D) receptor domain which is absent for the h5-HT(1B) receptor. The compounds described herein will be important tools to delineate the role of h5-HT(1D) receptors in migraine.